New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US.…
The MM Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US.…
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine…
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US.…
During EHA 2025, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the…
On June 18, 2025, the FDA approved tafasitamab in combination with rituximab plus lenalidomide for the treatment of adult patients with R/R FL.
On this show, Dr. Joseph Wu, former president of the American Heart Association, director of Stanford’s prestigious Cardiovascular Institute and head of the Stanford Drug…
The MM Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
